Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...
GlobalData on MSN
BMS reports positive results in Phase III SCOUT-HCM trial for oHCM
The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.
Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.
A significantly higher proportion of 4- to 7-year-olds with peanut allergy using the Viaskin Peanut patch were deemed ...
In picking Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services, President-elect Donald Trump is elevating a small but growing segment of the population that distrusts ...
SCOUT-HCM findings show mavacamten significantly reduces Valsalva LVOT gradient in adolescents with symptomatic oHCM.
US Health and Human Services Secretary Robert F. Kennedy Jr. has repeatedly claimed in public statements that most vaccines recommended for children in the US have not been tested against placebos, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback